NanoViricides Inc. has received approval from the regulatory agency ACOREP of the Democratic Republic of Congo (DRC) to begin a Phase II clinical trial of its antiviral drug candidate, NV-387, for the treatment of MPox. This follows earlier clearance from the DRC's national Ethics Committee, CNES, in May 2025. The company is finalizing and translating the required documentation for submission, after which patient recruitment for the trial can commence. No grant or funding from multiple organizations was announced in this update.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1099386) on November 10, 2025, and is solely responsible for the information contained therein.